(Q53443851)
Statements
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. (English)
Klaus Mross
Annette Frost
Simone Steinbild
Susanne Hedbom
Jochen Rentschler
Rolf Kaiser
Nicolas Rouyrre
Dirk Trommeshauser
Cornelia E Hoesl
Gerd Munzert
27 October 2008
26
34
5511-5517